NCT07206095Recruiting
Integrative Diagnosis for SCD and Other RADs
Integrative Diagnosis of Sickle Cell Disease (SCD) and Other Rare Anemia Disorders (RADs) for Personalized Medicine
Source: ClinicalTrials.gov · Last updated 3 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 16 Sept 2025
- Start date
- 13 Nov 2020
- Primary completion date
- 25 May 2025
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Diseases
- Sickle cell disease, Thalassaemia
- NCT number
- NCT07206095
What you commit to
- Study type: Observational
- Planned participants: 200
- From 13 Nov 2020 to the primary completion date, 25 May 2025
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Carrier traits in autosomal recessive hereditary anemias
Who the study is looking for
- Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia:
- Sickle cell disease
- Thalassemic syndromes
- Congenital dyserythropoietic anemia
- Enzymopathy
- Unstable Hemoblogin / Altered oxygen affinity
- Hereditary stomatocytosis
- Hereditary pyropoikilocytosis
- Hereditary spherocytosis with severe anemia (\<8 g/dL) or inconclusive diagnosis:
- Patient with chronic hemolytic anemia and red cell smear compatible, but with:
- EMA binding test: inconclusive or negative
- Genetic testing: no definitive diagnosis (VUS or no findings)
- Not transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included.
Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital de la Santa Creu i Sant Pau Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Sant Joan De Deu Coordinator of this site? Confirm its status | Esplugues de Llobregat | Spain | Recruiting |
| Hospital General de Granollers Coordinator of this site? Confirm its status | Granollers | Spain | Recruiting |
| Hospital Universitari Arnau de Vilanova Coordinator of this site? Confirm its status | Lleida | Spain | Recruiting |
| Consorci Sanitari del Maresme - Hospital de Mataró Coordinator of this site? Confirm its status | Mataró | Spain | Recruiting |
| Parc Tauli Hospital Universitari Coordinator of this site? Confirm its status | Sabadell | Spain | Recruiting |
| Hospital Universitari Mútua de Terrassa Coordinator of this site? Confirm its status | Terrassa | Spain | Recruiting |
| Consorci Sanitari de Terrassa Coordinator of this site? Confirm its status | Terrassa | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.